Skip to content

Study · Animal study (in vivo) · chick · 2001

1 result

Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model.

Koutrafouri V, Leondiadis L, Avgoustakis K, Livaniou E, Czarnecki J, Ithakissios DS, Evangelatos GP

Biochimica et biophysica acta1 Nov 2001Cited by 62 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In the chick chorioallantoic membrane model, thymosin alpha‑1 enhanced angiogenesis.

    In plain wordsIn chick embryo membranes, thymosin alpha‑1 increased the growth of new blood vessels.

    Outcome
    IncreaseAngiogenesis on chick chorioallantoic membrane
    Study

    chickn: not reported in source

    chick chorioallantoic membrane
    Outcome group
    Angiogenesis · Cardiovascular
    Studied dose
    0.016-6.66 nmoles per 10 microl aliquot · applied to the chorioallantoic membraneAs given in this study (chick).

    Source sentences

    Summary
    Tbeta4, ProT(alpha) and T(alpha)1 were found to enhance angiogenesis
    2 context sentences
    Summary · context
    The thymosin peptides tested were applied in 10 microl aliquots containing 0.01-4 nmoles of Tbeta4, Tbeta10 or Tbeta9, 0.016-6.66 nmoles of T(alpha)1, 4.1 pmoles-1.66 nmoles of ProT(alpha), and 4.4 pmoles-1.76 nmoles of ParaT(alpha).
    Summary · context
    The effect of alpha- and beta-thymosin peptides, namely prothymosin alpha (ProT(alpha)), thymosin alpha(1) (T(alpha)1), parathymosin alpha (ParaT(alpha)), thymosin beta(4) (Tbeta4), thymosin beta(10) (Tbeta10), and thymosin beta(9) (Tbeta9), on the angiogenesis process was investigated using the chi…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 18:17 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.